Pharmacokinetics and Pharmacodynamics of IFN-β1a in Healthy Volunteers

The pharmacokinetics of recombinant human interferon-β1a (IFN-β1a) (Rebif, Ares-Serono, Geneva, Switzerland) were investigated in healthy volunteers following intravenous (i.v.) administration of increasing single doses of the drug (22 μg/6 million international units [MIU], 44 μg/12 MIU, and 66 μg/18 MIU); i.v., intramuscular (i.m.), and subcutaneous (s.c.) administration of a 66-μg dose; and repeated s.c. administration of four 66-μg doses at 48-h intervals. The disposition of IFN-β1a followed triexponential decay after i.v. administration (half-lives 3 min, 42 min, and 22 h, respectively). After s.c. and i.m. administration, absorption was the rate-limiting factor in the terminal phase. The median absolute bioavailabilities were 30% and 27%, respectively. The accumulation ratio after repeated s.c. injections was 2.4, and a terminal half-life of 66 h was observed. Intracellular 2-5A synthetase activity and serum neopterin and β2-microglobulin concentrations increased after all IFN-β1a injections and rem...

[1]  W. Stroebel,et al.  Pharmacodynamics of recombinant IFN-beta during long-term treatment of malignant melanoma. , 1996, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[2]  F. Witter,et al.  Biologic response (antiviral) to recombinant human interferon alpha 2a as a aunction of dose and route of administration in healthy volunteers , 1987, Clinical pharmacology and therapeutics.

[3]  G. Antonelli,et al.  Physiological mechanisms of production and action of interferons in response to viral infections. , 1989, Advances in experimental medicine and biology.

[4]  S. Astolfi,et al.  Double-Blind Randomized Phase I Study on the Clinical Tolerance and Pharmacodynamics of Natural and Recombinant Interferon-β Given Intravenously , 1994 .

[5]  L. Giustini,et al.  Combination of beta-interferon and tamoxifen as a new way to overcome clinical resistance to tamoxifen in advanced breast cancer. , 1992, Anticancer research.

[6]  P. Altmeyer,et al.  Serum interferon level and (2'-5')oligoadenylate synthetase activity in lymphocytes during clinical interferon application. , 1985, Journal of interferon research.

[7]  A. Romano,et al.  Ten years of experience with human fibroblast interferon in treatment of viral ophthalmic infections. , 1988, Metabolic, pediatric, and systemic ophthalmology.

[8]  J. Monsonégo,et al.  Randomised double-blind trial of recombinant interferon-beta for condyloma acuminatum. , 1996, Genitourinary medicine.

[9]  R. P. Kinkel,et al.  Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis , 1997, Neurology.

[10]  G. Ebers,et al.  Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis , 1998, The Lancet.

[11]  T. Seki,et al.  Depression of Drug‐metabolizing Activity in the Human Liver by Interferon‐β , 1993, Hepatology.

[12]  P. Salmon,et al.  Pharmacokinetics and pharmacodynamics of recombinant human interferon-beta in healthy male volunteers. , 1996, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[13]  F. Rossiello,et al.  Effects of interferon-beta on steroid receptors, prostaglandins and enzymatic activities in human endometrial cancer. , 1996, Anticancer research.

[14]  Ludwig Kappos,et al.  Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis , 1998, The Lancet.

[15]  P. Kirby.  Interferon and genital warts: much potential, modest progress. , 1988, JAMA.

[16]  D. Goodin.  Interferon β treatment for multiple sclerosis , 1999, The Lancet.

[17]  B. Storer,et al.  Pharmacodynamics of biological response in vivo after single and multiple doses of interferon-beta. , 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[18]  F. Spertini,et al.  Influence of interferon β-1a dose frequency on PBMC cytokine secretion and biological effect markers , 1999, Journal of Neuroimmunology.

[19]  A. Munafo,et al.  Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta‐1a after intramuscular and subcutaneous administration , 1999, European journal of neurology.

[20]  M. Rogge,et al.  Pharmacokinetics and Pharmacodynamics of Interferon Beta-la (IFNβ-1a) in Healthy Volunteers after Intravenous, Subcutaneous or Intramuscular Administration , 1997 .

[21]  B. Tang,et al.  Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities , 1991, Clinical pharmacology and therapeutics.

[22]  B. Edwards,et al.  Comparative in vivo and in vitro activation of human natural killer cells by two recombinant alpha-interferons differing in antiviral activity. , 1984, Cancer research.

[23]  R. Michalevicz,et al.  Interferon-beta induced remission in a hairy cell leukemia patient resistant to interferon-alpha. , 1988, Leukemia research.

[24]  R. Rudick,et al.  Prescribing Recommendations For Interferon-Beta In Multiple Sclerosis , 1997, CNS drugs.

[25]  K. Hosoi,et al.  Highly Sensitive Enzyme Immunoassay of Human Interferon-β1 , 1989 .

[26]  H. Wang,et al.  Beta-interferon therapy in patients with poor-prognosis Kaposi sarcoma related to the acquired immunodeficiency syndrome (AIDS). A phase II trial with preliminary evidence of antiviral activity and low incidence of opportunistic infections. , 1990, Annals of Internal Medicine.

[27]  A. Alberti,et al.  Predictors of sustained response, relapse and no response in patients with chronic hepatitis C treated with interferon‐α , 1995, Journal of viral hepatitis.

[28]  D. Jones,et al.  Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N‐demethylation , 1996, Clinical pharmacology and therapeutics.

[29]  J. Illingworth,et al.  Recombinant human interferon- in the treatment of condylomata acuminata , 1997 .

[30]  G. Sica,et al.  Effect of natural beta‐interferon on cell proliferation and steroid receptor level in human breast cancer cells , 1987, Cancer.

[31]  J. Bornstein,et al.  Recombinant human interferon- for condylomata acuminata: a randomized, double-blind, placebo-controlled study of intralesional therapy , 1997, International journal of STD & AIDS.

[32]  A. Valéri,et al.  The lymphatic route. V. Distribution of human natural interferon-beta in rabbit plasma and lymph. , 1988, Journal of interferon research.

[33]  W. DeGrado,et al.  Sequence and structural homologies among type I and type II interferons , 1982, Nature.

[34]  C. Pozzilli,et al.  Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[35]  C. Granger,et al.  Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis , 1996, Annals of neurology.

[36]  S. Astolfi,et al.  Double-Blind Randomized Phase I Study on the Clinical Tolerance and Biological Effects of Natural and Recombinant Interferon-β , 1992 .